source
- Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpointA pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the drugmaker’s efforts to challenge Johnson & Johnson for the post-BCMA multip…Fierce Biotech · 7h ago↗ source
- Boston Scientific recalls spinal cord implant in wake of more than 1k serious injuriesBoston Scientific has issued another recall, this time for its spinal cord implant used to treat pain.Fierce Biotech · 8h ago↗ source
- Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durabilityInhibrx Biosciences’ CEO has argued that the 9.6 months of progression-free survival demonstrated by its OX40 agonist in a phase 2 study has proven the therapy’s durability in treating head and nec…